Greenwich LifeSciences stock rose after Phase 3 data showed GLSI-100 cut breast cancer recurrence rates by about 80% in new ...

As of Wednesday, December 17, Greenwich LifeSciences, Inc.’s GLSI share price has surged by 5.19%, which has investors ...

Greenwich LifeSciences ( ($GLSI) ) has provided an announcement. On December 18, 2025, Greenwich LifeSciences, Inc. held its Annual Meeting of ...

The company highlighted an 80% recurrence rate reduction in the open-label non-HLA-A*02 arm of the Phase III clinical trial. ...

You may not have heard of Greenwich LifeSciences (NASDAQ:GLSI) before today, but that is not stopping GLSI stock from soaring more than 2,000% on Wednesday. This comes as the biopharmaceutical company ...

Investing.com -- Greenwich LifeSciences (NASDAQ:GLSI) stock surged 37% after the clinical-stage biopharmaceutical company announced preliminary data showing an approximately 80% reduction in breast ...

Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,500 shares of the company on 01-10-2025. This trade was reported by Quiver Quantitative using data from a ...

Greenwich LifeSciences, Inc. is a late-stage biotech company focusing on developing an immunotherapy treatment for breast cancer. Their pipeline includes one drug, GLSI-100, currently in a phase 3 ...

Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,000 shares of the company on 01-02-2025. This trade was reported by Quiver Quantitative using data from a ...